Oncotelic CEO Vuong Trieu to Present Groundbreaking Research on Transforming Growth Factor Beta 2 (TGFB2) at SWCR 2025 Conference
Oncotelic Therapeutics (OTCQB:OTLC) has announced that CEO Vuong Trieu will deliver a featured presentation at the SWCR 2025 Conference on March 24th, focusing on Transforming Growth Factor Beta 2 (TGFB2) research. The presentation will explore TGFB2's role in cancer, lupus, and aging pathways.
The research highlights how high TGFB2 expression affects tumor-associated macrophage infiltration, disrupts antigen presentation, and creates resistance to immunotherapy. A significant portion will cover the development of OT-101, their antisense therapeutic targeting TGFB2, currently in Phase 3 clinical trials (STOP-PC study) for pancreatic ductal adenocarcinoma.
The presentation will examine how TGFB2 inhibition, either alone or combined with immune checkpoint inhibitors or interferon-based strategies, could enhance immune response and therapeutic efficacy. Dr. Trieu emphasizes TGFB2's role as a master regulator of immune suppression across multiple chronic diseases.
Oncotelic Therapeutics (OTCQB:OTLC) ha annunciato che il CEO Vuong Trieu terrà una presentazione principale alla SWCR 2025 Conference il 24 marzo, incentrata sulla ricerca del fattore di crescita trasformante Beta 2 (TGFB2). La presentazione esplorerà il ruolo del TGFB2 nel cancro, nel lupus e nei percorsi di invecchiamento.
La ricerca evidenzia come l'alta espressione di TGFB2 influisca sull'infiltrazione dei macrofagi associati ai tumori, interrompa la presentazione degli antigeni e crei resistenza all'immunoterapia. Una parte significativa sarà dedicata allo sviluppo di OT-101, la loro terapia antisenso mirata al TGFB2, attualmente in fase 3 di sperimentazione clinica (studio STOP-PC) per l'adenocarcinoma duttale pancreatico.
La presentazione esaminerà come l'inibizione del TGFB2, sia da sola che combinata con inibitori dei checkpoint immunitari o strategie basate sull'interferone, potrebbe migliorare la risposta immunitaria e l'efficacia terapeutica. Il Dr. Trieu sottolinea il ruolo del TGFB2 come regolatore principale della soppressione immunitaria in diverse malattie croniche.
Oncotelic Therapeutics (OTCQB:OTLC) ha anunciado que el CEO Vuong Trieu ofrecerá una presentación destacada en la SWCR 2025 Conference el 24 de marzo, centrada en la investigación del Factor de Crecimiento Transformante Beta 2 (TGFB2). La presentación explorará el papel del TGFB2 en el cáncer, el lupus y las vías del envejecimiento.
La investigación destaca cómo la alta expresión de TGFB2 afecta la infiltración de macrófagos asociados a tumores, interrumpe la presentación de antígenos y crea resistencia a la inmunoterapia. Una parte significativa se centrará en el desarrollo de OT-101, su terapia antisentido dirigida al TGFB2, que actualmente se encuentra en ensayos clínicos de fase 3 (estudio STOP-PC) para el adenocarcinoma ductal pancreático.
La presentación examinará cómo la inhibición de TGFB2, ya sea sola o combinada con inhibidores de puntos de control inmunitarios o estrategias basadas en interferón, podría mejorar la respuesta inmune y la eficacia terapéutica. El Dr. Trieu enfatiza el papel del TGFB2 como regulador maestro de la supresión inmune en múltiples enfermedades crónicas.
온코텔릭 테라퓨틱스 (OTCQB:OTLC)는 CEO인 뷔옹 트리우가 SWCR 2025 컨퍼런스에서 3월 24일에 발표를 할 것이라고 발표했습니다. 발표는 변형 성장 인자 베타 2 (TGFB2) 연구에 초점을 맞출 것입니다. 이 발표에서는 TGFB2가 암, 루푸스 및 노화 경로에서 어떤 역할을 하는지 탐구할 것입니다.
연구는 TGFB2의 높은 발현이 종양 관련 대식세포 침투에 미치는 영향, 항원 제시 방해 및 면역 요법에 대한 저항성을 생성하는 방법을 강조합니다. 중요한 부분은 현재 췌장관 선암에 대한 3상 임상 시험(STOP-PC 연구)에 있는 TGFB2를 타겟으로 하는 항센스 치료제 OT-101의 개발을 다룰 것입니다.
발표는 TGFB2 억제가 단독으로 또는 면역 체크포인트 억제제나 인터페론 기반 전략과 결합하여 면역 반응 및 치료 효능을 향상시킬 수 있는 방법을 검토할 것입니다. 트리우 박사는 TGFB2가 여러 만성 질환에서 면역 억제의 주요 조절자로서의 역할을 강조합니다.
Oncotelic Therapeutics (OTCQB:OTLC) a annoncé que le PDG Vuong Trieu donnera une présentation vedette lors de la SWCR 2025 Conference le 24 mars, axée sur la recherche sur le facteur de croissance transformant bêta 2 (TGFB2). La présentation explorera le rôle du TGFB2 dans le cancer, le lupus et les voies du vieillissement.
La recherche met en évidence comment une forte expression de TGFB2 affecte l'infiltration des macrophages associés aux tumeurs, perturbe la présentation des antigènes et crée une résistance à l'immunothérapie. Une partie importante portera sur le développement de OT-101, leur thérapie antisens ciblant le TGFB2, actuellement en phase 3 d'essai clinique (étude STOP-PC) pour l'adénocarcinome canalaire pancréatique.
La présentation examinera comment l'inhibition du TGFB2, seule ou en combinaison avec des inhibiteurs de points de contrôle immunitaires ou des stratégies basées sur l'interféron, pourrait améliorer la réponse immunitaire et l'efficacité thérapeutique. Le Dr Trieu souligne le rôle du TGFB2 en tant que régulateur principal de la suppression immunitaire dans de nombreuses maladies chroniques.
Oncotelic Therapeutics (OTCQB:OTLC) hat angekündigt, dass CEO Vuong Trieu am 24. März eine Hauptpräsentation auf der SWCR 2025 Conference halten wird, die sich auf die Forschung zum Transformierenden Wachstumsfaktor Beta 2 (TGFB2) konzentriert. Die Präsentation wird die Rolle von TGFB2 in Bezug auf Krebs, Lupus und Alterungswege untersuchen.
Die Forschung hebt hervor, wie eine hohe TGFB2-Expression die Infiltration von tumorrelevanten Makrophagen beeinflusst, die Antigenpräsentation stört und eine Resistenz gegen Immuntherapie schafft. Ein wesentlicher Teil wird sich mit der Entwicklung von OT-101, ihrer Antisense-Therapie, die auf TGFB2 abzielt und sich derzeit in Phase-3-Studien (STOP-PC-Studie) für das duktale Adenokarzinom der Bauchspeicheldrüse befindet, befassen.
Die Präsentation wird untersuchen, wie die Hemmung von TGFB2, allein oder in Kombination mit Immun-Checkpoint-Inhibitoren oder interferonbasierten Strategien, die Immunantwort und therapeutische Wirksamkeit verbessern könnte. Dr. Trieu betont die Rolle von TGFB2 als Hauptregulator der Immununterdrückung bei mehreren chronischen Krankheiten.
- None.
- None.
AGOURA HILLS, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC). Oncotelic Therapeutics, a leader in RNA-based therapeutics, is pleased to announce that Vuong Trieu, Ph.D., Chairman & CEO, will be delivering a featured presentation at the SWCR 2025 Conference on March 24th. His talk will highlight the central role of Transforming Growth Factor Beta 2 (TGFB2) in the convergence of disease pathways spanning cancer, lupus, and aging, as well as its potential as a therapeutic target in immuno-oncology.
Dr. Trieu's presentation, titled “Transforming Growth Factor Beta 2 in Aging, Cancer, Lupus, and Immuno-Oncology: A Convergence of Disease Pathways and Therapeutic Potential,” will delve into the immunosuppressive mechanisms of TGFB2 and its profound impact on solid tumors, autoimmune disorders, and age-related diseases. His research underscores how high TGFB2 expression fosters tumor-associated macrophage infiltration, disrupts antigen presentation, and drives resistance to immunotherapy—ultimately contributing to poor patient outcomes.
A key focus of the presentation will be the clinical development of OT-101, an antisense therapeutic targeting TGFB2, which is currently in Phase 3 clinical trials (STOP-PC study) for pancreatic ductal adenocarcinoma (PDAC). The talk will explore how TGFB2 inhibition—alone or in combination with immune checkpoint inhibitors or interferon-based strategies—may reshape the tumor microenvironment, boost immune response, and enhance therapeutic efficacy.
Dr. Vuong Trieu’s Vision for TGFB2 as a Therapeutic Target
“TGFB2 has emerged as a master regulator of immune suppression, not just in cancer but across multiple chronic diseases,” said Dr. Trieu. “Our work on OT-101 aims to neutralize TGFB2-driven resistance, unlocking the full potential of immunotherapy and improving outcomes for patients with pancreatic cancer, gliomas, and beyond.”
About Oncotelic Therapeutics
Oncotelic Therapeutics is a biotechnology company dedicated to advancing RNA-based therapeutics targeting immunosuppressive pathways in cancer and other diseases. The company’s lead program, OT-101, is being developed as a TGFB2 inhibitor with the potential to reverse immune evasion, enhance tumor response, and improve survival outcomes in oncology and immunology.
Presentation Details
- Event: SWCR 2025 Conference
- Date: March 24th, 2025
- Speaker: Vuong Trieu, Ph.D., Chairman & CEO, Oncotelic Therapeutics
- Title: Transforming Growth Factor Beta 2 in Aging, Cancer, Lupus, and Immuno-Oncology: A Convergence of Disease Pathways and Therapeutic Potential.
About Oncotelic
Oncotelic (f/k/a Mateon Therapeutics, Inc.), was formed in the State of New York in 1988 as OXiGENE, Inc., was reincorporated in the State of Delaware in 1992, and changed its name to Mateon Therapeutics, Inc. in 2016, and Oncotelic Therapeutics, Inc. in November 2020. Oncotelic is seeking to leverage its deep expertise in oncology drug development to improve treatment outcomes and survival of cancer patients with a special emphasis on rare pediatric cancers. Oncotelic has rare pediatric designation for Diffuse Intrinsic Pontine Glioma (“DIPG” through OT-101) through its
Oncotelic's Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this communication regarding strategy, future operations, future financial position, prospects, plans and objectives of management are forward-looking statements. Words such as "may", "expect", "anticipate" "hope", "vision", "optimism", "design", "exciting", "promising", "will", "conviction", "estimate," "intend," "believe", "quest for a cure of cancer", "innovation-driven", "paradigm-shift", "high scientific merit", "impact potential" and similar expressions are intended to identify forward-looking statements. Forward looking statements contained in this press release include, but are not limited to, statements about future plans related to the operations of the JV, taking the JV into an initial public offering or the success thereof, the progress, timing of clinical development, scope and success of future clinical trials, the reporting of clinical data for the company's product candidates and the potential use of the company's product candidates to treat various cancer indications as well as obtaining required regulatory approval to conduct clinical trials and upon granting of approval by the regulatory agencies, the successful marketing of the products; building and the success of our nanoparticle platform and the related success of launching the platform, the success of the launch of a company with a DAO infrastructure, the success of the entity and the plans surrounding the pet and animal health, the ability for the Company to register the tokens of Pet2DAO, the actual filing of a registration statement and approval of the PDAO, or any other tokens that we may launch, as registrable securities with the SEC through a registration statement, the ability of the tokens to be tradable or any value such tokens may have if they become tradable.. Each of these forward-looking statements involves risks and uncertainties, and actual results may differ materially from these forward-looking statements or may not occur at all. Many factors may cause differences between current expectations and actual results, including unexpected safety or efficacy data observed during preclinical or clinical studies, clinical trial site activation or enrollment rates that are lower than expected, changes in expected or existing competition, changes in the regulatory environment, failure of collaborators to support or advance collaborations or product candidates and unexpected litigation or other disputes, taking the Company or its affiliates through initial public offerings. These risks are not exhaustive, the company faces known and unknown risks, including the risk factors described in the Company's annual report on Form 10-K filed with the SEC on April 12, 2024 and in the company's other periodic filings. Forward-looking statements are based on expectations and assumptions as of the date of this press release. Except as required by law, the company does not assume any obligation to update forward-looking statements contained herein to reflect any change in expectations, whether because of new information, future events, or otherwise.
Contact Information:
For Oncotelic Therapeutics, Inc.:
Investor Relations
ir@oncotelic.com
FAQ
What is the significance of TGFB2 in Oncotelic's (OTLC) cancer research?
What stage is Oncotelic's (OTLC) OT-101 drug development currently in?
When and where will Oncotelic (OTLC) present their TGFB2 research findings?
How does Oncotelic's (OTLC) OT-101 treatment work against cancer?
What diseases does Oncotelic's (OTLC) TGFB2 research target?
